In 2010, Comabella et al. identified that CHI3L1 seems to be a prognostic biomarker for conversion to MS and development of disability utilizing the previously collected cerebrospinal fluid samples from MS patients by a mass spectrometry-based proteomic approach validating with ELISA (enzyme-linked immunosorbent assay) [75]. The gene discussed is CHI3L1; the disease is myeloid sarcoma.